(Q36684575)

15 August 2017

title

Clinical trials bureaucracy: unintended consequences of well-intentioned policy (English)

1 reference

15 August 2017

1

Robert M Califf

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

496-502

1 reference

Randomized clinical trials: slow death by a thousand unnecessary policies?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Gene therapy in the post-Gelsinger era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Toward protecting the safety of participants in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Integrating quality into the cycle of therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

American College of Cardiology/American Heart Association clinical practice guidelines: Part I: where do they come from?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

American College of Cardiology/American Heart Association clinical practice guidelines: Part II: evolutionary changes in a continuous quality improvement project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Payment for quality: guiding principles and recommendations: principles and recommendations from the American Heart Association's Reimbursement, Coverage, and Access Policy Development Workgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Lessons learned from recent cardiovascular clinical trials: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Research bureaucracy in the United Kingdom: seeking a balance: response from the Department of Health and COREC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Financial anatomy of biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

An audience with... Janet Woodcock discusses the role of the FDA in improving pharma productivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Rescuing the NIH before it is too late

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

ADHD drugs and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Breaking the camel's back: multicenter clinical trials and local institutional review boards

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Research ethics paperwork: what is the plot we seem to have lost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Data protection, informed consent, and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Monitoring and ensuring safety during clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Policies of academic medical centers for disclosing financial conflicts of interest to potential research participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Liability issues for data monitoring committee members

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Statistical quality control in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Physician remuneration in industry-sponsored clinical trials: the case for standardized clinical trial budgets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

Evaluating the quality of informed consent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774506073173

21 January 2018

Identifiers

DOI

10.1177/1740774506073173

1 reference

15 August 2017

1 reference